Clinical trial
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of…
NCT00375661 · Kyoto University, Other · Completed
Key facts
| NCT number | NCT00375661 |
|---|---|
| Title | Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC |
| Official title | Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma |
| Lead sponsor | Kyoto University, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | interferon-alfa-2b and ribavirin |
| Enrollment | 100 |
| Start date | Sep 1, 2006 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2013 |
| First posted | Sep 13, 2006 |
| Last update posted | Sep 2, 2015 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: